With a focus on collaboration, our team of investigators and support staff at SWDI bring their diverse backgrounds — in endocrinology, behavioral medicine, neuroscience and more — together to discover new ways of managing diabetes. Our research nurses, coordinators, program managers and research assistants have decades of experience conducting clinical trials. This extensive background allows us to thoroughly evaluate diabetes medications and devices and deliver exceptional care to our patients.
At SWDI, we engage in both investigator-initiated studies and sponsored clinical trials. The goal of our investigator-initiated research is to improve the quality of diabetes care. Our studies often involve technology and team-based care models and seek to remove barriers that contribute to health disparities in diabetes. Our interdisciplinary research team has obtained funding from NIH, foundations, pharmaceutical companies and other industry partners.
Between 2018 and 2023, Scripps Whittier Diabetes Institute has received over $1.5 million annually from NIH alone to fund investigator-initiated research studies. Additionally, we have participated in hundreds of clinical trials in partnership with leading companies, such as DexCom, Eli Lilly, Medtronic, Merck, Novo Nordisk, Pfizer and Sanofi.